Edited by: Pascal Demoly
Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study
Article first published online: 18 SEP 2012
© 2012 John Wiley & Sons A/S
Volume 67, Issue 11, pages 1437–1442, November 2012
How to Cite
Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study. Allergy 2012; 67: 1437–1442., , , , , , , , , .
- Issue published online: 10 OCT 2012
- Article first published online: 18 SEP 2012
- Manuscript Accepted: 23 JUL 2012
- allergic rhinitis;
- modified ARIA criterion;
A modified allergic rhinitis and its impact on asthma (ARIA) (m-ARIA) criterion to classify the severity of allergic rhinitis (AR) has recently been validated in both treated and untreated adult patients; however, such information in children is lacking. The aim of this study was to validate this m-ARIA severity criterion, which allows for discrimination between moderate and severe AR, in a large pediatric patient sample population.
The m-ARIA classification categorizes AR severity into mild (no affected items), moderate (1–3 affected items), and severe (all four affected items). We applied this modified criterion to untreated AR pediatric patients aged 6–12 years, through an observational, cross-sectional, and multicenter study. AR symptoms were assessed using the Total Four Symptom Score (T4SS), and the severity was evaluated by both ARIA severity items and visual analogue scale (VAS).
Allergic rhinitis pediatric patients (N = 1269) from 271 centers were included. Among them, 59.5% had intermittent and 40.5% persistent disease; 89.9% had moderate/severe AR using the original ARIA (o-ARIA) classification and 59.5% had moderate, while 30.5% had severe AR using the m-ARIA criterion. Using the m-ARIA, significantly higher T4SS and VAS scores were obtained when comparing severe with moderate AR.
The m-ARIA severity classification is a useful clinical tool to discriminate moderate from severe AR among untreated pediatric patients.